肝硬化患者LI-RADS 3病灶1年自然史多中心研究
这项回顾性研究纳入6个中心347例肝硬化患者的540个LI-RADS 3病灶,MRI随访12±3个月。28%的病灶在1年内进展,其中14%进展为LI-RADS 4,14%进展为LI-RADS 5。病灶大小、肝功能分级和病因是进展的独立预测因素,整合影像特征可将AUC从0.65提升至0.72。
要点
- LI-RADS 3病灶1年内28%进展,不应按良性对待
- 病灶≥9.5mm及Child-Pugh C级患者进展风险更高
- 影像特征(如强化包膜)可提升进展预测准确性
核心结论
- 约四分之一(28%)的LI-RADS 3病灶在1年内进展,其中14%至LI-RADS 4,14%至LI-RADS 5。
- 病灶大小、肝功能分级和病因是LI-RADS 3病灶进展的关键预测因素。
- 整合影像特征可将进展预测的AUC从0.65提高至0.72(p=0.01),支持个体化随访策略。
研究设计与样本
- 多中心多国回顾性研究,来自3个国家6个中心的347例肝硬化患者,共540个LI-RADS 3病灶。
- 所有病灶均有12±3个月的随访MRI,依据LI-RADS v2018标准重新评估。
- 采用广义线性混合效应模型及机器学习方法(LASSO、随机森林)评估进展预测因素。
关键影像表现/征象
- 强化包膜在单变量分析中与进展显著相关。
- 病灶大小以9.5mm为截断值与进展风险增加相关。
- 酒精相关性肝病为独立保护因素(OR: 0.24, 95% CI: 0.06-0.94)。
诊断标准与关键数值
- 病灶大小是进展的独立预测因素(OR: 1.12, 95% CI: 1.01-1.24,每增加1mm)。
- Child-Pugh C级与进展显著相关(OR: 8.36, 95% CI: 1.01-69.27)。
- 病灶大小截断值9.5mm与进展风险增加相关。
- 未治疗的丙型肝炎病毒在单变量分析中与进展显著相关。
- 临床与影像变量联合预测进展的AUC为0.72,单纯临床变量AUC为0.65(p=0.01)。
临床应用与阅片要点
- LI-RADS 3病灶不应视为良性,报告时应提示其1年内有28%的进展风险。
- 对≥9.5mm的LI-RADS 3病灶及Child-Pugh C级患者应考虑加强随访或缩短MRI复查间隔。
- 阅片时应关注强化包膜等影像征象,有助于风险评估分层。
局限性
- 回顾性研究设计存在选择偏倚和信息偏倚风险。
- 样本来源于多国多中心,不同中心的MRI设备和扫描方案可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the 1-year natural history of liver imaging reporting and data system (LI-RADS) 3 observations on contrast-enhanced MRI in cirrhotic patients across multiple international centers, and to identify clinical and imaging predictors of progression using multivariable and machine learning models.
MATERIALS AND METHODS: This retrospective study included 347 cirrhotic patients with 540 LI-RADS 3 observations from six centers across three countries, each with 12 (±3) months of follow-up MRI. Observations were reassessed using LI-RADS v2018 criteria. Generalized linear mixed-effects models and machine learning (LASSO, random forest) evaluated predictors of progression. Area under the curve (AUC) analysis assessed the predictive performance of clinical and imaging variables.
RESULTS: Within one year, 28% of LI-RADS 3 observations progressed: 14% to LI-RADS 4 and 14% to LI-RADS 5. Independent predictors of progression included lesion size, with an odds ratio (OR: 1.12, 95% CI: 1.01-1.24), Child-Pugh Class C (OR: 8.36, 95% CI: 1.01-69.27), and alcohol-related liver disease (OR: 0.24, 95% CI: 0.06-0.94). Enhancing capsule and untreated hepatitis C virus were significant in univariable analysis. Imaging features improved predictive accuracy, increasing AUC from 0.65 to 0.72 (p = 0.01). A lesion size cut-off of 9.5 mm was associated with increased progression risk.
CONCLUSION: One in four LI-RADS 3 observations progress within one year. Lesion size, liver function, and etiology are key predictors. Integration of imaging features enhances risk stratification and supports more personalized follow-up strategies for indeterminate liver lesions.
KEY POINTS: Question Identifying which LI-RADS 3 liver observations progress to malignancy remains challenging; evidence from large, standardized, multicenter MRI cohorts is lacking. Findings In this large multinational study, 28% of LI-RADS 3 observations progressed within one year; lesion size, liver dysfunction, and disease etiology were key independent predictors. Clinical relevance LI-RADS 3 observations show significant progression risk, with imaging features improving prediction models and guiding surveillance strategies for early HCC detection.
引用
- Asmundo, Mercaldo, Furtado, et al. A multicenter multinational retrospective study of the 1-year natural history of LI-RADS 3 observations in patients with cirrhosis. Eur Radiol. 2026. PMID: 41493547. doi:10.1007/s00330-025-12295-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。